Alcami, a U.S.-based pharmaceutical contract development and manufacturing organization (CDMO), is strengthening its capabilities with the addition of a 3,800 square foot non-GMP formulation development laboratory (FDL). The dedicated non-GMP formulation development space, which is co-located within the same facility as Alcami’s parenteral manufacturing operation that offers four isolator filling lines for liquid and lyophilized products, is ready to support customers with preclinical and ...